Karyopharm Therapeutics, Inc. Forecast, price target & analysts
Karyopharm Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation
Karyopharm Therapeutics, Inc. Classifications & Recommendation:
Karyopharm Therapeutics, Inc. Price Target
| Target Price | $4.50 |
| Price | $0.70 |
| Potential |
542.77%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Karyopharm Therapeutics, Inc. 2025 .
The average Karyopharm Therapeutics, Inc. target price is $4.50.
This is
542.77%
register free of charge
$7.00
899.86%
register free of charge
$2.00
185.67%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Karyopharm Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Karyopharm Therapeutics, Inc. stock has an average upside potential 2025 of
542.77%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 146.03 | 152.91 |
| 7.03% | 4.71% | |
| Net Margin | -107.26% | -58.30% |
| 33.44% | 45.64% |
6 Analysts have issued a sales forecast Karyopharm Therapeutics, Inc. 2024 . The average Karyopharm Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Karyopharm Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Karyopharm Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.25 | -0.71 |
| 38.12% | 43.20% | |
| P/E | negative | |
| EV/Sales | 0.98 |
7 Analysts have issued a Karyopharm Therapeutics, Inc. forecast for earnings per share. The average Karyopharm Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Karyopharm Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Karyopharm Therapeutics, Inc....
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
